RT Journal Article
T1 Using NS5B Sequencing for Hepatitis C Virus Genotyping Reveals Discordances with Commercial Platforms
A1 Chueca, Natalia
A1 Rivadulla, Isidro
A1 Lovatti, Rubén
A1 Reina, Gabriel
A1 Blanco, Ana
A1 Fernández Caballero, José Ángel
A1 Cardeñoso, Laura
A1 Rodríguez Granjer, Javier
A1 Fernández Alonso, Miriam
A1 Aguilera Guirao, Antonio
A1 Álvarez, Marta
A1 Galán, Juan Carlos
A1 García, Federico
AB We aimed to evaluate the correct assignment of HCV genotypes by three commercial methods—Trugene HCV genotyping kit (Siemens), VERSANT HCV Genotype 2.0 assay (Siemens), and Real-Time HCV genotype II (Abbott)—compared to NS5B sequencing. We studied 327 clinical samples that carried representative HCV genotypes of the most frequent geno/subtypes in Spain. After commercial genotyping, the sequencing of a 367 bp fragment in the NS5B gene was used to assign genotypes. Major discrepancies were defined, e.g. differences in the assigned genotype by one of the three methods and NS5B sequencing, including misclassification of subtypes 1a and 1b. Minor discrepancies were considered when differences at subtype levels, other than 1a and 1b, were observed. The overall discordance with the reference method was 34% for Trugene and 15% for VERSANT HCV2.0. The Abbott assay correctly identified all 1a and 1b subtypes, but did not subtype all the 2, 3, 4 and 5 (34%) genotypes. Major discordances were found in 16% of cases for Trugene HCV, and the majority were 1b- to 1a-related discordances; major discordances were found for VERSANT HCV 2.0 in 6% of cases, which were all but one 1b to 1a cases. These results indicated that the Trugene assay especially, and to a lesser extent, Versant HCV 2.0, can fail to differentiate HCV subtypes 1a and 1b, and lead to critical errors in clinical practice for correctly using directly acting antiviral agents
PB PLOS
YR 2016
FD 2016
LK http://hdl.handle.net/10347/32037
UL http://hdl.handle.net/10347/32037
LA eng
NO Chueca N, Rivadulla I, Lovatti R, Reina G, Blanco A, Fernandez-Caballero JA, et al. (2016) Using NS5B Sequencing for Hepatitis C Virus Genotyping Reveals Discordances with Commercial Platforms. PLoS ONE 11(4): e0153754. https://doi.org/10.1371/journal.pone.0153754
NO This work was supported in part by grants from Fondo de Investigación Sanitaria (PI12/01053, PI15/00713), RD12/0017/006 (Plan Nacional de I+D+I and Fondo Europeo de Desarrollo Regional-FEDER), and PI-0411-2014, Fundación Progreso y salud, Junta de Andalucía. Federico García has received a research extension grant from the Programa de Intensificación de la Actividad de Investigación del Servicio Andaluz de Salud
DS Minerva
RD 24 abr 2026